Egetis Wins FDA Priority Review for First Potential U.S. Treatment for MCT8 Deficiency

Egetis Therapeutics AB ( (SE:EGTX) ) has shared an announcement.

Egetis Therapeutics has announced that the U.S. Food and Drug Administration has accepted and validated its New Drug Application for Emcitate, or tiratricol, for the treatment of MCT8 deficiency. The filing has been granted Priority Review, with a Prescription Drug User Fee Act target action date set for Sept. 28, 2026, signaling an expedited regulatory pathway for the rare disease therapy.

If approved, Emcitate would become the first approved treatment in the U.S. for patients with MCT8 deficiency, a rare and devastating condition with high unmet medical need. The drug has Rare Pediatric Disease Designation and could earn a valuable Priority Review Voucher, which has recently commanded prices of $150 million to $205 million on the secondary market, potentially strengthening Egetis’s financial position ahead of a planned U.S. launch in the fourth quarter of 2026.

Egetis’s NDA is supported by a comprehensive data package from several clinical and observational studies, including Triac Trial I and II, ReTRIACt, the EMC Cohort and Survival studies, and a U.S. Expanded Access Program. During the Priority Review period, the company plans to work closely with the FDA while continuing to build its medical affairs and market access infrastructure, underscoring its transition toward becoming a commercial‑stage rare disease player in the U.S. market.

The most recent analyst rating on (SE:EGTX) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Egetis Therapeutics AB stock, see the SE:EGTX Stock Forecast page.

More about Egetis Therapeutics AB

Egetis Therapeutics AB is a Swedish biopharmaceutical company focused on developing treatments for rare endocrine and metabolic disorders. Listed on Nasdaq Stockholm under the ticker EGTX, the company is advancing its lead candidate Emcitate (tiratricol) for patients with monocarboxylate transporter 8, or MCT8, deficiency, addressing a severe, life‑shortening genetic disease with no approved therapies in the U.S.

Average Trading Volume: 788,922

Technical Sentiment Signal: Buy

Current Market Cap: SEK2.25B

For a thorough assessment of EGTX stock, go to TipRanks’ Stock Analysis page.